Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AGM Statement

26 Oct 2006 15:11

Original Investments PLC26 October 2006 ORIGINAL INVESTMENTS PLC Results of AGM * Merger with Vialogy approved by shareholders * Creates US-based technology business with clients including Cisco, Boeing and Evolution Petroleum * Change of name to ViaLogy PLC * Board changes to reflect focus on ViaLogy London, UK and Pasadena, CA - Original Investments Plc ("OI" or "Company") todayannounces that shareholders have approved its merger with California-basedtechnology group ViaLogy Corp through the acquisition of the remaining shares inViaLogy, Original Investments' largest holding. The Company will immediatelychange its name to ViaLogy PLC and will retain its listing on the AIM market ofthe London Stock Exchange (AIM). ViaLogy, based in Pasadena, CA, develops and markets signal processing solutionsfor technology companies. ViaLogy's flagship technology is Quantum ResonanceInterferometry (QRI), which is based on a system developed by NASA to detect andtrack weak sound signals sent from space and hitherto hidden by background'noise'. QRI can be adapted for a wide range of applications, including in thedefense, homeland security, first responder and oil and gas industries. ViaLogyhas signed development and product agreements this year with a number of theworld's leading companies, including Cisco Systems, Boeing and EvolutionPetroleum. OI has been a major investor in ViaLogy for the past three years, building up a43.76 per cent stake in the business (on a fully diluted basis). The other majorinvestor in ViaLogy is Aeris Holdings, a German-based venture capital company,which has supported the merger of OI and ViaLogy. "The merger of OI and ViaLogy creates a company with world-leading technologyand solid financial resources," said Terry Bond, managing director of OI, whowill become executive chairman of ViaLogy PLC. "We have been working towards themerger for over a year because we believe ViaLogy will have a major impact inmany high growth industries. The contracts with Cisco, Boeing, and Evolutionsigned during 2006 underline the significant potential of ViaLogy's technology." ViaLogy is working with Cisco on several fronts, including sensorinteroperability, border security, and the analysis of information on suchglobal threats as water contamination, food-borne diseases and bird flu. ForBoeing, ViaLogy is developing and demonstrating a proof-of-concept siliconelectronic eye. Based on bionic principles that replicate the optical movementsof certain insects and reptiles, the objective is to produce the next generationof low-power visual systems for autonomous missile interceptors. Evolution Petroleum Corporation of Texas has commissioned ViaLogy to use QRI toascertain the extent and density of oil deposits at several US oil explorationsites. At the annual meeting where shareholders approved the merger, the chairman andco-founder of OI, Jim Slater, announced his retirement from the board ofdirectors. "We have always believed, and we continue to believe, that ViaLogyhas the potential to be a really big winner," said Mr. Slater. "That is why wehave supported the business through its difficult formative years and why, nowthat its worth is being recognised by international players, we have arrangedthis merger. "The value of the Company will depend to a large extent on its management, and Ihave decided that I should not lead the team. ViaLogy is based in California,the flight time from UK is 11 hours, and frankly at my time if life that is justtoo long. In addition, we anticipate that ViaLogy will become an internationalcompany and this will involve a considerable amount of travel. It's the part ofthe job I have always disliked so I am passing on the baton to my friend andcolleague, Terry Bond." Mr. Slater emphasised that he had no present intention of selling hisshareholding in the Company. "On the contrary I have every confidence in the newteam and believe the Company has great potential to generate significant returnsfor shareholders" he said. Michael Kelly, formerly a managing partner with firstVentury, the German-basedventure capital group, will become chief executive of the combined business. Aninternational banker, he has held senior positions with Bank of America andDeutsche Bank in Germany. Dr. Sandeep Gulati, a co-founder of ViaLogy, will be chief technical officer. DrGulati headed the Ultracomputing Technologies Group at NASA's Jet Propulsion Lab(JPL). He has also served as principal scientist on programs including theDepartment of Defense's Joint Strike Fighter, NASA's Reusable Launch Vehicle andthe oil industry's DEEPLOOK Consortium. Other board members of the new ViaLogy include George Rehm, an internationallawyer who has worked with US presidential candidates on global trade andinvestment policy; and Dr. Robert Dean, a senior vice president with SAIC, thelargest employee-owned research and engineering company in the United States. A total of 91,903,314 new ordinary shares of 1 penny each in the Company("Consideration Shares") are being issued to the ViaLogy Corp shareholders asconsideration for the acquisition of the issued share capital of ViaLogy Corpnot already owned by the Company. Application has been made for the 91,903,314 Consideration Shares and the311,222,223 existing ordinary shares of 1 penny each in the Company ("OrdinaryShares") to be admitted to AIM and admission is expected to become effective at8.00 a.m. on 30 October 2006. The Consideration Shares will rank pari passu inall respects with the existing Ordinary Shares in issue. For further information please contact: Original Investments Tel: 01235 834734Terry Bond, Executive Chairman of ViaLogyFinancial Dynamics Tel: 0207 269 7169Ben AtwellJohn Gilbert Interviews with Michael Kelly and/or Dr. Sandeep Gulati can be arranged byconference call at any time or personally in London week commencing October 23. The OI annual report and the Admission Document giving full details of themerger will be found on www.originalinvestments.com. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
5th Nov 20207:00 amRNSDirectorate Change
3rd Nov 20207:00 amRNSPartnership with Take2 Health Limited
26th Oct 20207:00 amRNSHalf-year Trading update
23rd Oct 20207:00 amRNSCQC accreditation
21st Oct 20207:00 amRNSYourgene Genomic Services collaboration with Cytox
12th Oct 20207:00 amRNSElucigene DPYD tests to be used routinely in Wales
8th Oct 20207:00 amRNSStrategic reproductive health partnership in Japan
7th Oct 20207:00 amRNSIONA®Nx awarded contract with St George’s Hospital
5th Oct 20207:00 amRNSShare Incentive Plan
1st Oct 20204:59 pmRNSCorrection: Holding(s) in Company
1st Oct 20203:29 pmRNSHolding(s) in Company
28th Sep 20207:00 amRNSLaunch of Yourgene Genomic Services
25th Sep 20205:28 pmRNSIssue of Share Options
24th Sep 202010:00 amRNSDPD reimbursement in Germany
24th Sep 20207:00 amRNSDirector/PDMR Shareholding
23rd Sep 20205:20 pmRNSExercise of Options
23rd Sep 202012:25 pmRNSDirector/PDMR Shareholding
22nd Sep 20205:14 pmRNSResult of AGM
22nd Sep 20207:00 amRNSAGM Statement
21st Sep 20207:00 amRNSUS distribution agreement for DPYD &other products
9th Sep 20207:00 amRNSAGM update and investor presentation
3rd Sep 20207:00 amRNSIONA® Nx Launch
28th Aug 20207:00 amRNSNotice of AGM & Annual Report 2020
13th Aug 20207:00 amRNSTGA approves IONA® Nx for sale in Australia
11th Aug 20207:00 amRNSAdmission of Company Considerations Shares and TVR
7th Aug 20203:42 pmRNSHolding(s) in Company
7th Aug 20203:25 pmRNSHolding(s) in Company
7th Aug 20209:48 amRNSHolding(s) in Company
5th Aug 20201:15 pmRNSResult of Placing
5th Aug 20207:00 amRNS£16.15m Placing & Close of Accelerated Bookbuild
4th Aug 20205:13 pmRNSProposed Acquisition and Placing
3rd Aug 20207:00 amRNSCE-IVD Mark for Clarigene™ SARS-CoV-2 test
29th Jul 202012:05 pmRNSAppointment of Joint Broker
28th Jul 20207:00 amRNSFinal Results
13th Jul 20201:13 pmRNSNotice of Results
30th Jun 20207:00 amRNSCOVID-19 assay launched
19th Jun 20204:44 pmRNSIssue of Share Options
16th Jun 20207:00 amRNSCollaboration in COVID-19 testing
15th Jun 20207:00 amRNSCE-IVD mark received for Illumina-based IONA® test
26th May 202012:00 pmRNSHolding(s) in Company
26th May 20207:00 amRNSCOVID-19 testing service launch; business update
20th May 20207:00 amRNSExercise of Warrants and Options
20th Apr 20207:00 amRNSYear-end Trading update: Revenues increase 86%
16th Apr 20204:41 pmRNSSecond Price Monitoring Extn
16th Apr 20204:35 pmRNSPrice Monitoring Extension
14th Apr 20204:41 pmRNSSecond Price Monitoring Extn
14th Apr 20204:36 pmRNSPrice Monitoring Extension
14th Apr 20202:06 pmRNSSecond Price Monitoring Extn
14th Apr 20202:01 pmRNSPrice Monitoring Extension
7th Apr 20207:00 amRNSPresentation on ‘Adapting during crisis’

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.